Skip to main content
CalciMedica, Inc. logo

CalciMedica, Inc. — Investor Relations & Filings

Ticker · CALC ISIN · US38942Q2021 US Manufacturing
Filings indexed 461 across all filing types
Latest filing 2021-04-23 Regulatory Filings
Country US United States of America
Listing US CALC

About CalciMedica, Inc.

https://calcimedica.com/

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute inflammatory and immunologic diseases. The company specializes in the inhibition of calcium release-activated calcium (CRAC) channels, a therapeutic approach designed to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora™, is an intravenous formulation of the proprietary small molecule CRAC channel inhibitor, zegocractin. CalciMedica is developing Auxora for the treatment of life-threatening conditions with high unmet medical needs, including acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP), for which there are currently no approved disease-modifying treatments.

Recent filings

Filing Released Lang Actions
DEFA14A
Regulatory Filings
2021-04-23 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-23 English
MS INITIAL
Major Shareholding Notification
2021-04-15 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-04-12 English
PRIMARY DOCUMENT
Director's Dealing
2021-03-26 English
AMENDMENT NO. 1
Major Shareholding Notification
2021-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.